BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy. Currently, two proof-of-concept Phase 1b/2 studies with B-701 in 2nd line metastatic bladder cancer are being launched. There is significant unmet medical need in 2nd line advanced/metastatic bladder cancer, a disease in which patients have average progression free survival of two to three months, and survival of only six to nine months. To-date there is no approved therapy in the U.S. for 2nd line treatment.
In addition to exploring the efficacy of B-701 as a treatment for FGFR3-driven cancer, BioClin is testing the ability of B-701 to treat an orphan condition called achondroplasia, which is the most common form of human disproportionate dwarfism. In nearly 98% of individuals with achondroplasia, a single point-mutation in the FGFR3 gene is present. During bone development, FGFR3 normally functions to negatively regulate long bone growth. In achondroplasia, long bone growth is stunted due to the enhanced activity of FGFR3; thus blocking activation of this receptor has the potential to restore long bone growth.
Stephen Lau, Chief Executive Officer
Stephen Lau has extensive deal-making experience, having completed over 40 licensing, M&A, and financing transactions in recent years for biotechnology and other healthcare companies. Prior to co-founding BioClin, from 2008-2012, Stephen was Vice President of Corporate & Business Development at Anthera Pharmaceuticals, Inc. From 2003-2008, Stephen was at Amgen Inc., where he was responsible for managing and negotiating-in and out-licensing transactions. From 2001-2003, Stephen was a key member of the healthcare investment banking group at Adams, Harkness & Hill, where he helped biopharmaceutical and medical device companies raise over $2 billion in public and private financings, and executed numerous mergers and acquisitions transactions. Prior to investment banking, Stephen was a management consultant for Strategic Decisions Group, Braxton Associates/Deloitte Consulting and Hay Management Consulting, where he advised Fortune 500 healthcare and technology companies on strategic and portfolio management issues. Earlier in his career, he managed late-stage HIV clinical trials at University of California Davis Medical Center. Stephen received his B.A. in Microbiology and M.S. in Immunology from the University of California, Davis, and a Master's in Health Care Management from Harvard University.
Jocelyn Holash, Ph.D., Senior Vice President, Translational Sciences
Dr. Jocelyn Holash has over 15 years of experience in developing cancer therapeutics, she is helping to shape the clinical strategy for B-701 in cancer by developing indication, patient selection and biomarker strategies to best target B-701 to cancer patients. Through use of preclinical models, she is also helping to identify the most effective drug combinations. Prior to joining BioClin, she was at Novartis Institutes for Biomedical Research in Emeryville, CA from 2006-2014, where she led the Translational Biology group in Oncology. While at Novartis, she oversaw a group that contributed to the development of patient selection, biomarker and combination strategies for a number of small molecule and antibody therapeutics. Before joining Novartis, Jocelyn was at Regeneron Pharmaceuticals, Inc. in Tarrytown, NY from 1997-2005. At Regeneron she held several positions, eventually becoming the head of the Tumor Angiogenesis group. Her team performed preclinical studies to support the IND filing of VEGF Trap for cancer, as well doing basic angiogenesis cancer research. Dr. Holash received her Ph.D. from the University of Toronto and did postdoctoral work at the Burnham Institute in La Jolla, CA.
Eric A. Emery, Vice President, Manufacturing
Eric Emery has 25 years of biologics manufacturing experience, most recently as Vice President, Manufacturing, and General Manager of the PDL BioPharma manufacturing site in Brooklyn Park, MN. From 1996 to 2008 he provided leadership for PDL in the maturation of a pilot scale clinical supply operation to a commercially ready one, including the construction and qualification of a 2 x 10kL and 2 x 1 kL multi-product antibody manufacturing facility. Prior to PDL, Eric worked for Baxter from 1983 to 1996 in their Los Angeles plasma fractionation facility, purifying coagulation factor proteins in production and technical services roles. Prior to joining BioClin, Eric provided Foundation and Biology department direction for North Hennepin Community College in Brooklyn Park, MN, where he also sponsored undergraduate science research. Eric received a B.S. in Biology from California State University, Los Angeles.
Sue Hirabayashi, MBA, Senior Director Clinical Operations & Project Management
Sue Hirabayashi brings over 30 years of experience in the biotechnology and pharmaceutical industry and over 20 years in the planning and conduct of Phase I, II, III, and IV clinical studies. Her therapeutic areas of expertise have included immunology, oncology (biliary, lung, breast, colorectal, renal, melanoma, other solid tumors, leukemia, and lymphoma), infectious diseases, genetic disorders, pulmonary arterial hypertension and cardiology. Sue also has over 13 years of strategic planning and global project management including supervisory experience, leadership, organizational and communication skills. Prior to joining BioClin, Sue was most recently Director of the Clinical Operations Department at Talon Therapeutics (acquired by Spectrum Pharmaceuticals). Earlier in her career, she was in senior positions in project management and clinical operations with Actelion Pharmaceuticals, CoTherix, Exelixis, Telik, Sugen (acquired by Pharmacia, later Pfizer), Quintiles, Scios, Chiron, Genentech, and Hana Biologics. Sue received a MBA in Information Systems from Golden Gate University, San Francisco, CA; and a BS in Biology from St. Louis University, St. Louis, Missouri.
Board of Directors
Fouad Azzam, Ph.D., MBA
Fouad Azzam, PhD, MBA, joined LSP in 2007. He became a General Partner of the firm in that same year. Fouad’s prime focus and responsibility within LSP is to invest in unlisted securities and manage the firm's North American operations. Prior to joining LSP, Fouad was the Managing Director of Eastman Ventures, the investment arm of Eastman Chemical Company, where he built-up its Healthcare and Advanced Materials practice. In his role as Managing Director, he was responsible for numerous early- and late-stage investments across the US & Europe. Fouad brings a wealth of investment expertise to the LSP team. Prior to his role at Eastman Ventures, Fouad held senior leadership positions at Eastman Chemical including roles in Innovation, Corporate Strategy, Corporate Development (M&A) and New Business Development. His career also includes business, operating, and technology roles at Occidental Chemical and BFGoodrich. Among others, Fouad is currently a Director at Illuminoss Medical, a company championing minimally invasive solutions for the stabilization and treatment of bone fractures. Fouad’s academic credentials include a Master’s degree and PhD in Chemical Engineering from the University of Akron in Ohio. In addition, Fouad obtained an MBA in Finance & Strategy from the University at Buffalo in New York. Fouad lives in the greater Boston area with his wife and two children.
Cory Freedland, Ph.D.
Cory joined Sofinnova Ventures in 2015. He focuses on biopharmaceutical venture capital investments. Cory has been involved in the firm’s investments in Civitas (acquired by Acorda), NextCure, NuCana Biomed, Principia Biopharma, Spark Therapeutics (ONCE), and ZS Pharma (ZSPH, acquired by AstraZeneca).
Prior to Sofinnova, Cory was a Principal at Novo A/S. Prior to working in healthcare venture capital, he was a Vice President in the healthcare investment banking practice at Morgan Stanley, where he advised on over $12 billion of strategic and financing transactions in the biopharmaceutical and life science tools/diagnostics sectors. Before investment banking, Cory worked as a research scientist at Roche focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases.
Cory received his PhD in Pharmacology from Wake Forest University School of Medicine. He has an MBA from the Kellogg School of Management, and holds a BA in Psychology and Religious Studies from Connecticut College.
David Lacey, M.D., Board Observer
Dr. Lacey, formerly Senior Vice President of Discovery Research at Amgen, possesses over 20 years of scientific and senior leadership experience within the life sciences, focused on creating new medicines to make a difference in the lives of patients worldwide. During his tenure at Amgen, Dr. Lacey led an organization of more than 1200 scientists across a portfolio of drug discovery and development programs in the therapeutic areas of hematology/oncology, inflammation, metabolic disorders, and neuroscience. Dr. Lacey currently serves as a Board member for Nurix Inc., Atreca, and Inbiomotion SL, and acts as an advisor to a number of academic institutions, biotechnology companies, and is a Venture Partner at Ysios Capital.
Joël Jean-Mairet, Ph.D.
Joël Jean-Mairet is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology AG in 2001 and was its CEO until the company was successfully sold to F. Hoffmann La-Roche four years later. Glycart Biotechnology was the originator of Gazyva ® approved for B-CLL by the FDA as first-ever breakthrough therapy. He holds an MS in Biotechnology and a Ph.D. from the Swiss Federal Institute of Technology (ETH) in Zurich.
Joël is currently on the boards of directors of AM-Pharma B.V., Aura Biosciences Inc, Sanifit S.L. and Chairman of Inbiomotion S.L. He has been Chairman of the board of Cellerix (now Tigenix NYSE Euronext TIG), on the boards of Medlumics S.L. and Dermaluics S.L. and board observer at Biovex, Inc. (now Amgen). Joël has earned numerous awards, including the Gold Medal of Wall Street Journal’s Europe Innovation Award in 2001.
Christian M. Richard, M.S, MBA
Christian Richard joined Tekla Capital Management in March of 2015 as Senior Vice President of Research. Previously, he was a Partner/Head of Research for Merlin Biomed Private Equity/Merlin Nexus for 12 years. Merlin Nexus is a cross-over life sciences fund focused on negotiated transactions in both late-stage private and public companies. Prior to Merlin Nexus, he spent almost five years in the Allergy/Immunology Group at the Schering-Plough Research Institute. He has a BS in Cellular and Molecular Biology from Purchase College and both an MS in Biochemistry and an MBA in Finance from NYU.
Mårten Steen, M.D., Ph.D.
Dr. Mårten Steen is a partner at HealthCap, and previously worked with global business development at Merck Serono, focusing on both product and technology licensing. Prior to Merck Serono, he was a medical associate with HealthCap. Mårten is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a Ph.D. in Clinical Chemistry in 2003. He is the author of 16 scientific papers and published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management. He serves on the board of Wilson Therapeutics AB, Immune Targeting Systems Ltd, and deputy member of the board of Nordic Nanovector AS. He previously served on the board of Ultragenyx Inc (RARE) and FerroKin Biosciences prior to its acquisition by Shire.
Joe Turner has been an active board member for a number of private and public biopharmaceutical companies. Joe previously served on the Board of Directors of several publicly-held biotechnology companies: Allos Therapeutics, Inc. (acquired by Spectrum Pharmaceuticals), QLT, Inc., and SGX Pharmaceuticals, Inc., (acquired by Lilly). Joe has also served on the Board of Directors of privately-held biotechnology companies: NovaCardia, Inc. (acquired by Merck & Co., Inc.), Sequel Pharmaceuticals, Inc., and ApopLogic Pharmaceuticals, Inc. Joe is currently a member of the Board of Directors of Alexza Pharmaceuticals, Inc., Corcept Therapeutics, Inc., Kythera Biopharmaceuticals, and Sophiris Bio. Joe also currently serves on the Board of Managers of Swarthmore College and the Board of Directors of the Linda Crnic Institute for Down Syndrome Research at the University of Colorado Medical School.
Previously, Joe was the Senior Vice President of Finance and Administration and Chief Financial Officer at Myogen, Inc. from 1999 until its acquisition by Gilead Sciences, Inc., in November 2006. Prior to Myogen, he served as Vice President, Finance and Chief Financial Officer at Centaur Pharmaceuticals, Inc. from 1997 to 1999 and as Vice President, Finance and Chief Financial Officer of Cortech, Inc. from 1992 to 1997. From 1979 to 1991, Joe worked at Eli Lilly and Company, where he held a variety of financial management positions both within the United States and abroad. Joe received his M.B.A. from the University of North Carolina at Chapel Hill, an M.A. in Molecular Biology from the University of Colorado at Boulder and a B.A. in Chemistry from Swarthmore College.